Vicore Pharma - Interim report April-June 2023

Vicore Pharma - Interim report April-June 2023 Stockholm, August 24, 2023 - Vicore Pharma Holding AB (STO: VICO) (“Vicore”), unlocking the potential of a new class of drugs – angiotensin II type 2 receptor agonists (ATRAGs), publishes the interim report for the second quarter 2023.Important ev...

Related Keywords

Stockholm ,Sweden ,Swedish ,Michael Buschle ,Vicore Pharma ,Carl Johan Dalsgaard ,Ahmed Mousa ,Hans Jeppsson ,Pieris Pharmaceuticals ,Vicore Pharma Holding ,Vicore Pharma Us Inc ,Pharma Holding ,Chief Business Officer ,Johan Dalsgaard ,Securities Markets ,Nasdaq Stockholm ,